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Abstract
Undercarboxylated osteocalcin (ucOC) improves glucose metabolism; however, its
effects on endothelial cell function are unclear. We examined the biological effect of
ucOC on endothelial function in animal models ex vivo and human cells in vitro.
Isometric tension and immunohistochemistry techniques were used on the aorta of
male New Zealand white rabbits and cell culture techniques were used on human
aortic endothelial cells (HAECs) to assess the effect of ucOC in normal and high‐
glucose environments. Overall, ucOC, both 10 and 30 ng/ml, did not significantly
alter acetylcholine‐induced blood vessel relaxation in rabbits (p > .05). UcOC
treatment did not cause any significant changes in the immunoreactivity of cellular
signalling markers (p > .05). In HAEC, ucOC did not change any of the assessed
outcomes (p > .05). UcOC has no negative effects on endothelial function which is
important to reduce the risks of off target adverse effects if it will be used as a
therapeutic option for metabolic disease in the future.
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1 | INTRODUCTION
The link between diabetes‐associated hyperglycaemia and the de-
velopment of cardiovascular disease is well established (Ebong et al.,
2013). Hyperglycaemia is a major independent risk factor for the
development of atherosclerosis and vascular disease (Bornfeldt &
Tabas, 2011; Rask‐Madsen & King, 2013). Exposure of endothelial
cells to high glucose levels perturbs cell homeostasis, and an im-
balance of biochemical pathways contributes ultimately to en-
dothelial dysfunction (Bakker, Eringa, Sipkema, & van Hinsbergh,
2009). This imbalance causes several pathological effects, principally,
the inability of the endothelium to regulate vasodilation and vaso-
constriction (Bonetti, Lerman, & Lerman, 2003; Cahill & Redmond,
2016; Lerman & Zeiher, 2005).
Recent advances in the understanding of bone physiology have
established bone as an active endocrine organ. Osteocalcin (OC) in
its undercarboxylated form (ucOC) plays a role in glucose regula-
tion and energy metabolism (Levinger et al., 2017; Li, Zhang, Yang,
Li, & Dai, 2016). ucOC has been linked to enhanced secretion of
insulin from pancreatic beta cells, improvements in insulin sensi-
tivity, and regulation of glucose homeostasis (Ferron, Hinoi,
Karsenty, & Ducy, 2008; Lin et al., 2017; Oury et al., 2011). Given
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these bioactive effects, it has been suggested that ucOC be tar-
geted as a therapeutic treatment for metabolic diseases, including
diabetes (Villafan‐Bernal, Sanchez‐Enriquez, & Munoz‐Valle, 2011).
However, some studies report that OC may be associated with
endothelial dysfunction and atherosclerosis. For example, in men
and women with diabetes, lower levels of circulating total OC (tOC)
have been associated with increased pulse wave velocity,
intima–media thickness (IMT), and vascular complications (Q. Guo
et al., 2017; Kanazawa et al., 2009). On the other hand, higher
levels of tOC have also been associated with increased plaque de-
velopment and IMT men and women with diabetes (Kanazawa et al.,
2011; Reyes‐Garcia et al., 2012). Overall, the evidence is conflicting
and the exact role of tOC and ucOC in the vasculature is unclear
(Millar, Patel, Anderson, England, & O'Sullivan, 2017; Tacey et al.,
2018). One major limitation of previous studies is that they only
examined the serum levels of circulating tOC, and not its individual
forms, in particular ucOC. Given the bioactivity of ucOC, its direct
effect on blood vessels must be explored before any use as a
therapeutic option for hyperglycaemia.
The aim of the current study was to determine (a) whether
ucOC has an effect on endothelium‐dependent and endothelium‐
independent vasodilation in rabbit aorta following incubations in
normal and high glucose solutions, and (b) whether the treatment of
human aortic endothelial cells (HAECs) with ucOC alters en-




Male New Zealand White rabbits were housed in individual cages
on a 12‐h light/dark cycle at 21°C, with access to water and
standard chow diet ad libidum. At 12 weeks of age, the rabbits
were randomised onto a normal chow diet (Guinea pig and rabbit
pellets) or an atherogenic diet (a normal diet combined with 1%
methionine, 0.5% cholesterol and 5% peanut oil (#SF00‐218) for
4 weeks (Zulli & Hare, 2009). At the completion of the 4‐week
diet, the rabbits were weighed and then sedated (0.25 mg/kg
medetomidine) and anaesthetised (4% isoflurane) before ex-
sanguination via severing of the inferior vena cava. A random
blood glucose sample was obtained from the inferior vena cava
immediately upon exsanguination and was recorded with a blood
glucose monitor (Freestyle Optimum Neo). A serum sample was
obtained from the inferior vena cava to determine insulin con-
centration. Insulin was measured using an enzyme‐linked im-
munosorbent assay (ELISA) Kit and was completed according to
the manufacturer's instructions (#90186; Australian Biosearch).
This study was approved by the Victoria University Animal Ethics
Committee (#14/005) and complied with the Australian National
Health and Medical Research Council code for the care and use of
animals for scientific purposes (8th edition).
2.2 | Isometric tension myography
The abdominal aorta (immediately before the iliac bifurcation) was
dissected and placed in ice‐cold Krebs solution ([mM] 118 NaCl,
4.7 KCl, 1.2 MgSO4·7H2O, 1.2 KH·2PO4, 25 NaHCO3, 11.7 glucose,
and 1.25 CaCl). The aorta was cleaned of connective tissues, cut into
rings (2–3mm) and placed in individual organ baths containing Krebs
warmed to 37°C and bubbled with 95% O2/5% CO2. This was fol-
lowed by 30‐min acclimatisation. Blood vessel reactivity was mea-
sured via an isometric tension organ bath system (Zultek
Engineering), as previously described (El‐Hawli et al., 2017; R. M.
Smith, Rai, Kruzliak, Hayes, & Zulli, 2019). In brief, the aortic rings
were carefully mounted on parallel hooks (one of which was con-
nected to a force transducer) and stretched to a basal tension twice
over a 1‐h period. Thereafter, the vessels were incubated for 2 h in
normal Krebs solution (11.7 mM glucose) or high‐glucose Krebs so-
lution (20mM glucose) which has previously shown to cause a re-
duction in endothelium‐dependent vasodilation (X. Guo, Liu, Chen, &
Guo, 2000; Taylor & Poston, 1994). Each organ bath was refreshed
every 30min with its respective Krebs solution. Aortic rings were
constricted with phenylephrine (3 × 10−7M) until a plateau occurred
followed by a 5‐min incubation with either 10 or 30 ng/ml ucOC
(Glu13, 17, 20, osteocalcin [1–46] [mouse] trifluoroacetate salt [H‐
6552.0500; Auspep]) or control solution [Krebs]. The concentration
of ucOC administered to each aortic ring was chosen based on
physiological ranges (Hiam et al., 2019). Blood vessel reactivity was
determined via cumulative dose‐response curves to the
endothelium‐dependent vasodilator acetylcholine (ACh) or with the
endothelium‐independent vasodilator sodium nitroprusside (SNP) in
half‐log increments (10−8 to 10−5M). The response of the vessels was
measured on a software program (MEDIDAQ) which displays the
tension of the vessel in grams. The log dose of ACh/SNP that pro-
duced the maximal relaxation was indicated by the Emax and the EC50
as the log dose that produced 50% of the Emax. The area under the
curve (AUC) was determined as the total area of relaxation below
the phenylephrine plateau.
2.3 | Immunohistochemistry
Following the isometric testing, aortic rings were immediately placed
into 4% paraformaldehyde, left overnight, and then transferred into
1X phosphate‐buffered saline at 4°C. This was followed by paraffin
processing (Microm STP120) and embedding in paraffin blocks.
Sections were cut at 5 μm, deparaffinised in xylene, rehydrated and
blocked with 1% goat serum in 10mm Tris‐Cl (pH 7.4) for 20min.
Primary mouse monoclonal antibodies anti‐3‐nitrotyrosine [39B6]
(#61392; Abcam) and endothelial nitric oxide synthase (eNOS) type
III (#610296; BD Biosciences), p‐protein kinase B (Akt) 1/2 [Ser473]
(NOVNB10056749; Novus Biologicals) and p‐mammalian target of
rapamycin (mTOR) [59. Ser 2448] (SANTSC‐293133; Santa Cruz
Biotechnology) at 1:100 dilution were applied overnight. Samples
were also prepared where the primary antibody was omitted from
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the solution as a negative control. Samples were subsequently in-
cubated with antimouse immunoglobulin G for 1 h (Immpress HRP
Reagent Kit MP‐7452; Vector Laboratories). Diaminobenzidine
(#550880; BD Biosciences) was applied as a chromogen before
counterstaining with hematoxylin, dehydration, and mounting in di-
butylphthalate polystyrene xylene (Arora, Hare, & Zulli, 2012). All
chemicals and reagents were supplied by Sigma‐Aldrich unless
otherwise specified.
2.4 | Immunohistochemistry quantification
Images of each aortic ring were taken at ×40 magnification (Leica
DFC 450F; Leica Microsystems). The endothelium was traced and
the degree of brown immunoprecipitate (indicative of positive anti-
genic sites) was quantified using the MCID programme (MCID 7.0;
Interfocus), as previously described (Qaradakhi et al., 2017; Zulli
et al., 2006). Researchers were blinded to the samples for quantifi-
cation. The proportional intensity (arbitrary unit) of brown im-
munoprecipitate was calculated as a ratio of colour intensity to
proportional area, normalised to the negative control. Finally, the
immunoreactivity of each protein was calculated based on a fold
change from the respective control vessel (the control ring from the
normal diet or atherogenic diet groups).
2.5 | Cell culture
HAECs were purchased from PromoCell and maintained in com-
mercial endothelial cell media with supplements (PromoCell) con-
taining 1% penicillin–streptomycin (Sigma‐Aldrich) in a humidified
incubator (5% CO2, 37°C), as previously established (Millar, Zala,
Anderson, & O'Sullivan, 2019). Cells were used for experiments at
passages 4 and 5. Cells were treated with either 5.6 mM normal
glucose media (NG) or 16mM high glucose media (HG) for 7 days
with or without ucOC (10 ng/ml) to induce endothelial dysfunction.
Media and cell lysates were collected at the end of the experiments.
Each experiment was repeated independently three times. Human
uncarboxylated osteocalcin (ucOC; amino acids 1–49, [Glu17, 21,
24]) was purchased from US Biological (O8060‐09C‐USB). D‐(+)‐
glucose was purchased from Sigma‐Aldrich (#I9278 and #G7021).
Cell lysis buffer was purchased from Cell Signalling Technology
(#9803) and was supplemented with protease and phosphatase in-
hibitors (A32959; Thermo Fisher Scientific).
2.6 | ELISAs, lactate dehydrogenase activity assay,
and total protein content
Secreted interleukin‐6 (IL‐6), vascular cell adhesion molecule‐1
(VCAM‐1), endothelin (ET), and monocyte chemoattractant
protein‐1 (MCP‐1) were measured in cell culture media by ELISA
as per manufacturers' instructions (catalogue numbers DY206,
DT809, DY1160, and DY279; R&D Systems). A lactate dehy-
drogenase (LDH) (Colorimetric) Assay Kit (category number
ab102526; Abcam) was performed on cell media as per the man-
ufacturer's instructions. A bicinchoninic acid protein assay was
performed to quantify the total protein content in the cell lysates
collected at the end of the experiments (P. K. Smith et al., 1985).
A total osteocalcin ELISA which does not differentiate between
uncarboxylated and carboxylated osteocalcin was performed to
assess predicted and actual concentrations of ucOC added to ex-
perimental wells and to validate the purchased protein (DY1419;
R&D Systems).
2.7 | Statistical analysis
Statistical analyses were performed using GraphPad Prism (version
8.0 Graphpad Software Inc). Unpaired Student's t test was used to
compare between the normal and atherogenic diet and between the
NG and HG incubations in the ex vivo rabbit model. A one‐way
analysis of variance (ANOVA) was used to analyse the effect
of the ucOC treatment on blood vessel relaxation and im-
munohistochemistry staining. One‐way ANOVA was also used to
detect differences between groups following the in vitro cell culture
experiments. Post hoc analysis was completed using Fisher's least
significance difference test. All data are reported as mean ± SEM and
statistical analysis was conducted at the 95% level of significance
(p < .05). Trends were reported if p was between 0.05 and 0.09. Ef-
fect sizes are commonly used to study the clinical relevance of in-
tervention and show the magnitude of the effect that it is producing
(Maylor, Zakrzewski‐Fruer, Stensel, Orton, & Bailey, 2019; Rodevand
et al., 2019; Silva, Lacerda, & da Mota, 2019). The Cohen's d (d)
equation was used to examine the magnitude of effect. A large effect
is considered when d > 0.8, a medium effect between 0.5 and 0.79
and a small effect between 0.2 and 0.49 (Cohen, 2013).
3 | RESULTS
3.1 | Atherogenic diet versus normal diet in
rabbits
No difference in body mass occurred between the rabbits fed a
normal diet and those fed the atherogenic diet (p > .05, d = 0.16;
Figure 1a). Circulating blood glucose levels was increased by 25%
following the atherogenic diet compared to the normal diet (p < .01,
d = 1.48; Figure 1b). Circulating insulin concentration did not change
following both diets, suggesting the presence of insulin resistance in
the animals fed with atherogenic diet (p > .05, d = 0.44; Figure 1c).
Endothelial function was not altered by the atherogenic diet as
shown by EC50, Emax, and AUC (p > .05 for all, d = 0.03, 0.08 and 0.07,
respectively; Figure 1d) compared to the normal diet.
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F IGURE 1 Comparison between the 4‐week normal and atherogenic diets for (a) Body mass, (b) random blood glucose concentration, (c)
random insulin concentration, and (d) blood vessel relaxation. All data mean ± SEM. AD, atherogenic diet; BGL, blood glucose level; ND, normal
diet. **p < .01 between diets
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F IGURE 2 ACh‐induced endothelium‐dependent dose‐response curves in abdominal aorta following a 5‐min ucOC preincubation. ND (a–c)
and AD (d–f) fed rabbits. All data mean ± SEM. Numbers above columns represent the effect size (Cohen's d) in comparison to the respective
NG/HG control group. 10 ucOC, 10 ng/ml ucOC treatment; 30 ucOC, 30 ng/ml ucOC treatment; ACh, acetylcholine; AD, atherogenic diet; AUC,
area under the curve; HG, high glucose media; ND, normal diet; NG, normal glucose media; ucOC, undercarboxylated osteocalcin
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3.2 | Blood vessel reactivity
The 20mM high‐glucose incubation did not alter endothelium‐
dependent vasodilation following either the normal diet (d = EC50:
0.17; Emax: 0.18) or atherogenic diet (d = EC50: 0.52; Emax: 0.01; p > .05
for all; Figure S1). UcOC (10 and 30 ng/ml) did not alter ACh‐induced
blood vessel relaxation in rabbits fed a normal or atherogenic diet or
in aortic rings incubated in NG or HG solution (p > .05; Figure 2a–f;
Table 1). The 10 ng/ml ucOC treatment produced a trend in Log EC50
(p = .05–.09; Table 1) and moderate improvements in AUC (∼10%;
Figure 2c) as indicated by Cohen's d in NG and HG from normal diet‐
fed rabbits. Administration of ucOC (10 and 30 ng/ml) before SNP
induced endothelium‐independent relaxation did not significantly alter
any measure of blood vessel relaxation (Figure S2 and Table S1).
3.3 | Immunohistochemistry
The ucOC (10 and 30 ng/ml) treatment did not cause any significant
changes in the immunoreactivity of NT, eNOS, p‐Akt, or p‐mTOR
following either the normal or atherogenic diet (p > .05; Figure 3a–h).
Analysis of Cohen's d revealed moderate to large increases in the
reactivity of eNOS in HG incubated aorta following the normal diet
(10 ng/ml ucOC = 2.5‐fold and 30 ng/ml ucOC 0.9‐fold) following
ucOC administration. This was also found in the NG incubated aorta
following the atherogenic diet (30 ng/ml ucOC = 1.2‐fold;
Figure 3c,d). ucOC administration also increased the phosphoryla-
tion of mTOR at ser2448 in the NG condition following both normal
(10 ng/ml ucOC = 1.3‐fold and 30 ng/ml ucOC = 2.2‐fold) and
atherogenic diets (10 ng/ml ucOC = 1‐fold and 30 ng/ml = 0.9‐fold),
while less effect occurred in the HG incubated vessels (Figure 3g,h).
3.4 | Cell culture
Total protein content was unaltered between the three experimental
conditions (Figure 4a). After 7 days cultured in HG media (16mM),
the secretion of IL‐6, VCAM‐1, ET‐1, MCP‐1 and LDH were increased
compared to NG controls (53%, 64%, 29%, 108% and 30%, respec-
tively; p < .01 for all; Figure 4b–f). The addition of ucOC to HG media
did not attenuate the increases in IL‐6, VCAM‐1, ET‐1, MCP‐1 or
LDH activity (p > .05 for all). The HG + ucOC was also significantly
increased compared to the NG controls for IL‐6, VCAM‐1, MCP‐1
and LDH (p < .01 for all). There was a trend for HG + ucOC to be
elevated above the NG controls for ET‐1 (p = .07).
4 | DISCUSSION
We report that acute ucOC treatment has no negative, or positive,
effect on endothelial function or endothelial cell homeostasis in
rabbit aorta ex vivo or human vascular cells in vitro in the presence
or absence of high glucose.
Functionally, an impairment of endothelium‐dependent vasodi-
lation is one of the first signs of endothelial dysfunction, and a
marker of early atherosclerosis development (Bonetti et al., 2003;
Esper et al., 2006). Previous research has examined endothelium‐
dependent vasodilation in the thoracic aorta of apolipoprotein E
(ApoE)−/−mice ex vivo following tOC administration. Following a 12‐
week high‐fat diet with daily injections of vehicle or tOC (30 ng/g),
the dilation of the thoracic aorta was improved by 20% in the tOC‐
treated mice compared to the vehicle‐treated mice (Dou et al., 2014).
However, the tOC‐treated mice also had improvements in body
weight, blood glucose concentration, lipids and inflammatory
TABLE 1 Log EC50 and Emax results from ACh‐induced endothelium‐dependent dose‐response curves in abdominal aorta
n Log EC50 ± SEM p vs. NG/HG d vs. NG/HG Emax ± SEM p vs. NG/HG d vs. NG/HG
ND+NG 9 −7.67 ± 0.15 −81.54 ± 3.05
ND +NG + 10 ng/ml ucOC 8 −7.96 ± 0.08 .07^ 0.82 −82.46 ± 3.72 NS 0.09
ND+NG + 30 ng/ml ucOC 8 −7.88 ± 0.09 NS 0.58 −83.16 ± 2.4 NS 0.2
ND +HG 9 −7.73 ± 0.07 −83.1 ± 2.77
ND +HG + 10 ng/ml ucOC 8 −7.96 ± 0.08 .09^ 1.06 −84.21 ± 3.38 NS 0.12
ND+HG + 30 ng/ml ucOC 8 −7.59 ± 0.13 NS 0.46 −81.43 ± 2.61 NS 0.21
AD +NG 8 −7.68 ± 0.17 −82.18 ± 2.59
AD +NG + 10 ng/ml ucOC 8 −7.76 ± 0.12 NS 0.18 −83.62 ± 2.15 NS 0.21
AD +NG + 30 ng/ml ucOC 8 −7.96 ± 0.12 NS 0.68 −80.3 ± 1.54 NS 0.31
AD +HG 7 −7.93 ± 0.18 −82.09 ± 2.56
AD +HG + 10 ng/ml ucOC 7 −7.89 ± 0.12 NS 0.1 −78.08 ± 4.47 NS 0.42
AD +HG + 30 ng/ml ucOC 7 −7.74 ± 0.1 NS 0.49 −79.3 ± 1.94 NS 0.46
Note: 10 ucOC, 10 ng/ml ucOC treatment; 30 ucOC, 30 ng/ml ucOC treatment. ^p = .05–.099.
Abbreviations: ACh, acetylcholine; AD, atherogenic diet; d, Cohen's d; HG, high glucose media; n, total number of animals; ND, normal diet; NG, normal
glucose media; NS, not significant; ucOC, undercarboxylated osteocalcin.





































































































































































































































































F IGURE 3 Immunoreactivity of (a and b) NT, (c and d) eNOS, (e and f) p‐AKT, and (g and h) p‐mTOR in aorta following normal diet (a,c,e,h)
and atherogenic diet (b,d,g,i). Reactivity is calculated based on intensity of staining present on the endothelium which is an arbitrary unit and
expressed as fold change from the respective NG/HG control group. Numbers above columns represent the effect size (Cohen's d) in
comparison to the respective NG/HG control group. All data mean ± SEM. eNOS, endothelial nitric oxide synthase; HG, high glucose; NG, normal
glucose; NT, nitrotyrosine; p‐Akt, phosphorylated protein kinase B; p‐mTOR, phosphorylated mammalian target of rapamycin; ucOC,
undercarboxylated osteocalcin
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markers (Dou et al., 2014). Therefore, whether improved blood
vessel relaxation occurred as a direct response to OC or as a result
of improved metabolic parameters cannot be determined from this
study. Recently, ucOC was detectable within the endothelium of
rabbit arteries, and administration of ucOC (10 ng/ml) improved
endothelium‐dependent relaxation of the rabbit aorta (Qaradakhi
et al., 2019). Suggesting that ucOC is present in the vasculature and
can direct regulate blood vessel function.
As ucOC is known to exert a metabolic function (Ferron et al.,
2008), we sought to determine if the effect of ucOC on blood vessel
function remains under high glucose conditions. In the current
study, the aortic sections from rabbits incubated for 2 h in 20 mM
high glucose solution did not have altered endothelium‐dependent
vasodilation, which is in contrast to previous studies (X. Guo et al.,
2000; Taylor & Poston, 1994). Similarly, the atherogenic diet, which
has previously been shown to cause endothelial dysfunction in
rabbit aorta (Qaradakhi et al., 2019; Zulli & Hare, 2009), did not
cause dysfunction in this study. It is unclear why in the endothelial
dysfunction did not occur, but we were able to examine the effect
of ucOC following acute high glucose incubations and in an insulin‐
resistant state following the atherogenic diet. Whilst the adminis-
tration of 10 ng/ml ucOC produced a trend towards an improve-
ment in endothelium‐dependent relaxation, overall ucOC did not
alter relaxation under any condition. This finding is in contrast to
previous studies, but suggests that ucOC may not have a biological
role in the regulation of endothelial function. Importantly, there























































































































































F IGURE 4 Human aortic endothelial cells (HAECs) cultured in NG media (NG; 5.5 mM) or HG media (HG; 16mM) with or without ucOC
(10 ng/ml). (a) Total protein content, (b) IL‐6, (c) VCAM‐1, (d) endothelin‐1, (e) MCP‐1 and (f) LDH activity were measured after 7 days. Numbers
above columns represent the effect size (Cohen's d) in comparison to NG column. **p < 0.01, ***p < .001 compared to NG. n = 12 for each
condition from three experimental repeats. All data mean ± SEM. HG, high glucose; IL‐6, interleukin 6; LDH, lactate dehydrogenase; MCP‐1,
monocyte chemoattractant protein‐1; NG, normal glucose; ucOC, undercarboxylated osteocalcin; VCAM‐1, vascular adhesion molecule 1
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To examine the effect of ucOC on smooth muscle cells, in-
dependent of the endothelium, we administered ucOC to rabbit
aorta before completing dose‐response curves with SNP, a nitric
oxide donor. The acute ucOC treatment had no effect on SNP‐
induced, endothelium‐independent relaxation of the rabbit aorta and
suggests that any effect of ucOC in the vasculature is likely occurring
via endothelium‐dependent mechanisms.
Previous in vivo experiments in mice demonstrated an im-
provement in endothelial relaxation following treatment with tOC
(30 ng/ml) for 12 weeks. The authors suggested that the activation of
the phosphatidylinositol 3‐kinase (PI3k)/Akt/eNOS signalling path-
way was necessary to induce the enhancement in relaxation (Dou
et al., 2014). In the current study, Akt and eNOS immunoreactivity
was unaltered by treatment with ucOC. This is the same for the
presence of NT and mTOR and suggests that the duration of ucOC
treatment may not have been long enough to induce changes in the
cellular signalling mechanisms necessary to alter endothelial func-
tion. Overall, in the current study, ucOC did not have a regulatory
effect on the vasoactivity of rabbit aorta. Whilst the focus of this
study was predominantly on vasodilation, the examination of the
proposed signalling pathways that ucOC activates in endothelial cells
did not reveal any changes following ucOC treatment. It is possible
that a different dose of ucOC or a longer incubation is needed before
ACh‐induced relaxation to cause a change in the signalling pathways
or functional outcomes. This should be explored in future studies.
Endothelial cells have an important role in the maintenance of
vascular homeostasis and the protection against the development of
vascular disease (Brown, Shantsila, Varma, & Lip, 2017). Recent data
suggest that ucOC may be involved in endothelial function. Admin-
istration of ucOC (25 and 100 ng/ml), but not the carboxylated form
(cOC), increases eNOS phosphorylation in HAECs in a dose‐
dependent manner (Kondo et al., 2016). Similarly, in HAEC incuba-
tion of ucOC for 1 h caused a dose‐dependent increase in eNOS
phosphorylation at serine 1177. This was associated with dose‐
dependent increases of Akt, an upstream activator of eNOS and of
nitric oxide (Jung et al., 2013). Furthermore, increased eNOS, Akt
and PI3k phosphorylation was reported in human umbilical cord vein
endothelial cells following tOC (100 ng/ml) and ucOC (5 ng/ml)
treatment (Dou et al., 2014; Q. Guo et al., 2017). Altogether, these
studies support the hypothesis that OC, via ucOC, has an active role
in endothelial cells, protecting against pathological processes and
improving endothelial function via the PI3K/Akt signalling pathway
(Tacey et al., 2018). However, we have recently reported some
conflicting findings, ucOC treatment (10 ng/ml) did not alter the
phosphorylation of Akt, mTOR, nuclear factor‐κB and several other
markers of intracellular signalling in HAECs (Millar, Anderson, &
O'Sullivan, 2019). In addition, ucOC did not alter markers of angio-
genesis in HAEC, such as migration and matrix degradation and in-
flammatory markers that are commonly involved in endothelial
dysfunction (Millar, Anderson et al., 2019). Furthermore, under acute
and chronic inflammatory conditions that mimic an atherogenic en-
vironment, ucOC (10 ng/ml) had no anti‐inflammatory effect in
human HAECs (Millar, Zala, et al., 2019). These results are supported
by the findings of the current study. Here we show that ucOC ad-
ministration did not attenuate inflammatory or dysfunction markers
altered by high glucose treatment. One potential explanation for our
finding is due to the dose of ucOC used. We used 10 ng/ml of ucOC,
which is lower than what was used in some previous studies; how-
ever, it is in the physiological range (Hiam et al., 2019). Future re-
search may complete a dose‐response curve to determine if there is
an optimal dose of ucOC. Overall, our findings suggest that ucOC
does not regulate endothelial cell signalling or function in physiolo-
gical or pathophysiological conditions.
Although it was not examined in this study, there is evidence to
suggest a link between OC and the advanced stages of athero-
sclerotic cardiovascular disease development, in particular the de-
velopment of vascular calcification (Levinger et al., 2017). The
mineralisation of plaque during atherosclerosis development is si-
milar to the formation of bone within the skeleton (Zhu, Mackenzie,
Farquharson, & Macrae, 2012). The form of OC present within cal-
cified plaques is yet to be identified, given the role of cOC in the
mineralisation of bone it is possible that cOC is responsible for the
association with vascular calcification. The exact mechanisms by
which OC mediates the interaction with vascular calcification is still
to be fully identified, but should be investigated in future studies.
A limitation of this study is that the atherogenic diet and the
20mM glucose incubation which have previously been shown to
cause endothelial dysfunction, did not alter endothelial function, in-
dicating heterogeneity of blood vessel dysfunction. However, we
were still able to assess the effect of ucOC on endothelial function in
normal and high glucose environments.
In conclusion, acute ucOC treatment does not have a negative,
or positive, effect on endothelial function or endothelial cell home-
ostasis in rabbit aorta or human vascular cells in the presence or
absence of a high glucose environment. As no adverse effects oc-
curred, it is proposed that ucOC may be considered as a therapeutic
option for metabolic disease.
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